1. Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model.
- Author
-
Lund KV, Simonsen TG, Kristensen GB, and Rofstad EK
- Subjects
- Adenocarcinoma metabolism, Adenocarcinoma therapy, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell therapy, Chemoradiotherapy mortality, Female, Follow-Up Studies, Humans, Image Processing, Computer-Assisted methods, Middle Aged, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local therapy, Prognosis, Survival Rate, Tissue Distribution, Uterine Cervical Neoplasms metabolism, Uterine Cervical Neoplasms therapy, Young Adult, Adenocarcinoma pathology, Carcinoma, Squamous Cell pathology, Contrast Media pharmacokinetics, Magnetic Resonance Imaging methods, Models, Statistical, Neoplasm Recurrence, Local pathology, Uterine Cervical Neoplasms pathology
- Abstract
Background: There is significant evidence that DCE-MRI may have the potential to provide clinically useful biomarkers of the outcome of locally advanced cervical carcinoma. However, there is no consensus on how to analyze DCE-MRI data to arrive at the most powerful biomarkers. The purpose of this study was to analyze DCE-MRI data of cervical cancer patients by using the Brix pharmacokinetic model and to compare the biomarkers derived from the Brix analysis with biomarkers determined by non-model-based analysis [i.e., low-enhancing tumor volume (LETV) and tumor volume with increasing signal (TVIS)] of the same patient cohort. Material and methods: DCE-MRI recordings of 80 patients (FIGO stage IB-IVA) treated with concurrent cisplatin-based chemoradiotherapy were analyzed voxel-by-voxel, and frequency distributions of the three parameters of the Brix model ( A
Brix , kep , and kel ) were determined. Moreover, risk volumes were calculated from the Brix parameters and termed RV- ABrix , RV- kep , and RV- kel , where the RVs represent the tumor volume with voxel values below a threshold value determined by ROC analysis. Disease-free survival (DFS) and overall survival (OS) were used as measures of treatment outcome. Results: Significant associations between the median value or any other percentile value of ABrix , kep , or kel and treatment outcome were not found. However, RV- ABrix , RV- kep , and RV- kel correlated with DFS and OS. Multivariate analysis revealed that the prognostic power of RV- ABrix , RV- kep , and RV- kel was independent of well-established clinical prognostic factors. RV- ABrix , RV- kep , and RV- kel correlated with each other as well as with LETV and TVIS. Conclusion: Strong biomarkers of the outcome of locally advanced cervical carcinoma can be provided by subjecting DCE-MRI series to pharmacokinetic analysis using the Brix model. The prognostic power of these biomarkers is not necessarily superior to that of biomarkers identified by non-model-based analyses.- Published
- 2019
- Full Text
- View/download PDF